Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20”

Showing 12 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00634933
What this trial is testing

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Who this might be right for
Arthritis, Rheumatoid
Pfizer 222
Not applicableStudy completedNCT01042509
What this trial is testing

Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease

Who this might be right for
Graft vs Host Disease
Hospital Universitario Dr. Jose E. Gonzalez 15
Testing effectiveness (Phase 2)Ended earlyNCT01458548
What this trial is testing

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Who this might be right for
Post-transplantation Lymphoproliferative Disorder
Charite University, Berlin, Germany 70
Testing effectiveness (Phase 2)Study completedNCT00291928
What this trial is testing

HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II

Who this might be right for
Arthritis, Rheumatoid
GlaxoSmithKline 201
Testing effectiveness (Phase 2)Looking for participantsNCT06002659
What this trial is testing

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

Who this might be right for
B-cell Lymphoma
Uppsala University 18
Large-scale testing (Phase 3)Looking for participantsNCT07321093
What this trial is testing

The Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Biocad 292
Early research (Phase 1)Looking for participantsNCT06725524
What this trial is testing

JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Non Hodgkin Lymphoma
Shanghai JMT-Bio Inc. 186
Testing effectiveness (Phase 2)Ended earlyNCT01156922
What this trial is testing

B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome

Who this might be right for
Chronic Fatigue SyndromeMyalgic Encephalomyelitis
Haukeland University Hospital 8
Testing effectiveness (Phase 2)WithdrawnNCT00004039
What this trial is testing

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Not applicableStudy completedNCT01448928
What this trial is testing

Zevalin Post-marketing Surveillance in Japan

Who this might be right for
Non-Hodgkin's Lymphoma (NHL)
Spectrum Pharmaceuticals, Inc 400
Testing effectiveness (Phase 2)Ended earlyNCT00100737
What this trial is testing

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin Lymphoma
Chiron Corporation 300
Testing effectiveness (Phase 2)Study completedNCT00290667
What this trial is testing

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Who this might be right for
Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group 586

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation